Compare Citius Pharmaceuticals Inc (CTXR) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Harley-Davidson Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Harley-Davidson Inc trades at $25.23 (market cap $2.64B). The key difference: Harley-Davidson Inc is far larger — about 180.3× Citius Pharmaceuticals Inc's market cap, and Harley-Davidson Inc pays a 2.93% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | HOG | |
|---|---|---|
Market Cap | $14.64M | $2.64B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $31.03 |
52-Week Low | $0.53 | $17.19 |
Enterprise Value | $10.86M | $3.04B |
Dividend Yield | — | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Harley-Davidson (HOG) trades at $25.39, up 0.99% with a bullish technical signal from moving averages. The stock shows mixed fundamentals with declining revenue from $5.8B in 2022 to $4.5B in 2025 and net income dropping to $339M, though valuation ratios remain attractive with P/E of 13.16 and P/B of 0.87. Recent news highlights production returning to US facilities and Q2 2026 earnings scheduled for July 23, 2026.
The outlook is cautiously optimistic with analyst consensus at Hold (65.71%) and price target of $23.40 below current price. Key opportunities include cost cuts and US production shift, while risks involve margin pressure and competitive threats. The stock faces headwinds from recent earnings misses but maintains dividend payments and institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
